What We're Reading: COVID-19 Testing Lags; Malaria Drugs Get Emergency Approval; Shutdown Extended
March 30th 2020The reasons behind coronavirus disease 2019 (COVID-19) testing lags; FDA issues emergency authorization of malaria drugs for treatment of COVID-19; an expert from the University of Washington predicts that there could be at least 1 more extension of social distancing, beyond President Trump's announcement extending coronavirus guidelines to April 30.
What We're Reading: EpiPen Auto-Injectors; Drink More Water; Protect Your Mental Health
March 25th 2020The FDA issues safety alerts for EpiPen and EpiPen Jr Auto-Injectors; we should be drinking more water to reduce the effects of increased sugar intake; experts suggest actively working to protect mental health while on lockdown.
FDA Clears New Dose of Trastuzumab Biosimilar From Samsung Bioepis
March 25th 2020The FDA Tuesday cleared a new dose of Samsung Bioepis’ trastuzumab biosimilar Ontruzant, which is yet to be launched in the United States. The approval is for a 420-mg multidose vial of Ontruzant. The biosimilar was first approved as a 150-mg single-dose vial by the FDA in January 2019 across all indications for the reference product, Herceptin.
Researchers Evaluate Infusion Parameters for IgPro20
March 19th 2020Two studies discussed the feasibility of different parameters for the infusion of a product for patients with primary immunodeficiency disorder in abstracts prepared for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.
Cost-Effectiveness, Impact of AIT on Costs Among Published AAAAI Research
March 18th 2020Is it cost-effective to prescribe epinephrine to every patient on allergen immunotherapy (AIT)? Does AIT have an impact on healthcare costs? These and other issues were included among the research prepared and published for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.
What We're Reading: Amazon Shipments; New COPD Treatment; High-Profile Mergers on Hold
March 18th 2020Amazon has decided to suspend nonessential item shipments; study results show patients with chronic obstructive pulmonary disease (COPD) benefited from a fluticasone furoate/umeclidinium/vilanterol combination inhaler; disruptions from the coronavirus now extend to proposed mergers among industry giants.
COVID-19 Roundup: Administration Seeks COVID-19 Aid; Report Warns of Grim Mortality Toll
March 18th 2020The Trump administration asked Congress for billions in COVID-19 assistance for Americans while a report said government responses in both the United States and the United Kingdom were suddenly being influenced by a grim analysis forecasting half a million to over 2 million deaths if the virus is allowed to run rampant without nonpharmaceutical interventions—ie, social isolation.
IgPro20 Well Tolerated by Most Patients With PID, According to Phase 4 Study Data
March 18th 2020High infusion parameters for pump-assisted and manual push 20% subcutaneous immunoglobulin (SCIg), or IgPro20, were well tolerated by patients with primary immunodeficiency disorder (PID), according to a recent abstract prepared for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.
Research Examines Factors That Complicate Pediatric Asthma
March 18th 2020Included among the abstracts prepared and published for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting are several that looked at the clinical and psychosocial factors that complicate asthma in pediatric patients. A few are highlighted here.
What We're Reading: Adolescent Mental Health; CASPIAN Phase 3 Trial Results; Tips to Destress
March 17th 2020Adolescents who have had family members deported or detained were linked with poor psychological outcomes; AstraZeneca's phase 3 CASPIAN trial failed to meet its primary endpoint; tips on how to destress when you feel overwhelmed.
COVID-19 Roundup: Coronavirus Now a National Emergency, With Plans to Increase Testing
March 14th 2020President Donald Trump on Friday declared the novel coronavirus a national emergency, which unlocks billions of dollars in federal funding to fight the disease’s spread. He also announced the creation of a website to direct symptomatic individuals to drive-through testing locations.